About the Breast Cancer Therapy Expert Group (BCTEG)
The BCTEG is a group of expert physicians and clinical researchers who have dedicated their careers to the treatment of patients with breast cancer. The purpose of the group is to meet periodically to discuss important developments related to breast cancer management, with a particular emphasis on new findings and/or areas where guidance from established bodies, such as the National Comprehensive Cancer Network (NCCN) and the American Society for Clinical Oncology (ASCO), may be unresolved, or less well established. The goal is to elicit the group’s opinions on a given topic as it relates to their own clinical practices, and more importantly, how this might impact those practicing in the community setting, where breast cancer is only one of many tumor types encountered. Importantly, this article is not intended to replace any existing guidance, or to be construed as an exhaustive review of the topic in question. Rather, its main aim is to present a concise synopsis of the relevant data in this area, and summarize the opinion of the expert group, as gleaned from the meeting discussion.
Meeting objectives and role of funding sources
In a previous meeting, the group addressed several key issues related to endocrine therapy for hormone receptor-positive (HR+) early breast cancer (EBC) [1]. A second BCTEG meeting was convened in late August 2017 with the goal of conducting an informal roundtable discussion on the use of cyclin-dependent kinase (CDK) 4/6 inhibitors for HR+ metastatic breast cancer (mBC). An unrestricted educational grant for this activity was provided by Eli Lilly and Company, Pfizer Inc., and Novartis Pharmaceuticals Corporation, with additional support from Total Health Conferencing, a medical education company. The faculty were compensated for their participation, and topics of discussion were selected by the faculty and by Total Health Conferencing. It is recognized that many of the panelists may have relationships with corporate entities, both related and unrelated to the topic in question; content of the discussions, and any expert opinions presented herein, was intended to be based on the panelists’ own expert clinical experience and insight, and is understood not to be influenced by any corporate relationship or interest.
Anzeige
Introduction
Dysregulation of the cell cycle is recognized as a salient feature of cancer cells [2‐4]. The cyclin-dependent kinases (CDKs) 4 and 6 play an important regulatory role in the initiation of mitosis in the mammalian cell cycle [2‐4]. Under normal conditions, progression through the cell cycle is inhibited by the retinoblastoma gene product (pRb), which represses the E2F transcription factor family and activation of its downstream targets [2, 4]. In response to activating signals such as growth factors or cell adhesion molecules, cyclin D1 is produced, and interacts with CDKs 4 and 6 to form a complex which phosphorylates pRb and lifts the repression on E2F, allowing it to activate downstream targets, and permitting quiescent cells to irreversibly enter the DNA synthesis (S) phase of the cell cycle [2‐4]. There are several findings that have implicated the CDK 4/6 pathway in breast cancers; these include overexpression and/or amplification of D-type cyclins (e.g. CCND1) and CDK 4 [2, 3]. Preclinical work in breast cancer cell lines from Finn and coworkers also showed that estrogen receptor-positive (ER+) cell lines were most sensitive to CDK 4/6 inhibition, and evidence for an apparent synergism between CDK 4/6 inhibitors and endocrine therapy (tamoxifen) [2]. Collectively, these findings have led to the development of CDK 4/6 inhibitors as potential therapeutic agents in breast cancer. Whereas first-generation CDK 4/6 inhibitors lacked sufficient specificity, resulting in disappointing clinical efficacy and unacceptable toxicities, second-generation agents are now available that have shown efficacy in breast cancer in both the preclinical and clinical settings; these agents include palbociclib, ribociclib, and abemaciclib [5‐14].
CDK 4/6 inhibitors: brief summary of clinical evidence in mBC
The seminal clinical data supporting the use of CDK 4/6 inhibitors in combination with endocrine therapy for mBC are summarized in Table 1, and includes the PALOMA-1, -2, and 3, MONALEESA-2 and -7, and MONARCH-1, -2, and -3 studies for palbociclib, ribociclib, and abemaciclib, respectively. Of note, whereas both palbociclib and ribociclib were approved for use in mBC at the time of the roundtable discussion, abemaciclib had not yet been approved. Since that time, results from MONARCH-3 have been subsequently been reported, and abemaciclib was approved for use in the mBC setting by the United States Food and Drug Administration (US FDA) based on the MONARCH-1 and 2 trials [15]. As outlined in Table 1, all of these agents have been shown to significantly and robustly improve the endpoint of progression-free survival (PFS) in women with HR+ mBC when used in combination with selected endocrine therapies. Significant improvement in overall response rate (ORR) and clinical benefit rate (CBR) with the combination therapy (compared to endocrine therapy alone) has also been observed across these studies (Table 1). There are important differences in terms of toxicities with the three agents, which, however, may, at least in part, relate to their differential specificity for the CDKs [3]. Importantly, an overall survival (OS) advantage has not yet been documented in the setting of mBC (Table 1); thus, the choice of which therapeutic line in which to initiate a CDK 4/6 inhibitor is not mandated.
Agent | Trial | Study Type and Treatments | Population Studied | Key Efficacy Findings | Key Safety Findings |
|---|---|---|---|---|---|
Palbociclib | PALOMA 1 | Phase 2; Open-label Palbociclib or Placebo + Letrozole | Postmenopausal; HR+, HER2−, ABC ~43% of pts had prior CT | Median PFS 10.2 mo for placebo + letrozole vs. 20.2 mo for palbociclib + letrozole (HR 0.488, 95% CI 0.319–0.748; P = 0.0004). ORR (43% vs. 33%; P = 0.047) and CBR (81% vs. 58%; P = 0.0009) favored palbociclib + letrozole | Gr 3/4 Events (palbociclib vs. placebo) Neutropenia 54% versus 1% Leucopenia 19% versus 0% Fatigue 4% versus 1% No febrile neutropenia or neutropenia-related infections |
PALOMA 2 | Double-blind, Phase 3 Palbociclib or Placebo + Letrozole | Postmenopausal; HR+, HER2− ABC No prior therapy for advanced disease | Primary efficacy endpoint, PFS, met; favors palbociclib (24.8 mo vs. 14.5 mo; HR 0.58; 95% CI 0.46; 0.72; P < 0.001) Consistent benefit in PFS across subgroups OS data immature at time of analysis ORR 42.1% versus 34.7%; P = 0.06 CBR 84.9% versus 70.3%; P < 0.001 | Most common toxicities (30% or more patients) included neutropenia, leucopenia, fatigue, nausea, arthralgia, alopecia Febrile neutropenia occurred in 1.8% of palbociclib treated patients versus 0% in placebo group | |
PALOMA 3 | Randomized; Double-blind, Phase 3 Palbociclib or Placebo + Fulvestrant ~ 1/3 with prior CT for metastatic disease | HR+, HER2− ABC Progression on prior endocrine therapy | Primary efficacy endpoint, PFS, met at interim analysis; favors palbociclib (9.2 mo vs. 3.8 mo; HR 0.42; 95% CI 0.32; 0.56; P < 0.001) Benefit observed across major subgroups examined based on HRs. OS data immature at time of analysis ORR 10.4% versus 6.3%; P = 0.16 CBR 34.0% versus 19.0%; P < 0.001 | Toxicities occurring in 30% or more patients (Palbociclib vs. Placebo); Gr 3/4, Palbociclib versus Placebo Neutropenia (78.8% vs. 3.5%); 62.0% versus 0.6% Leukopenia (45.5% vs. 4.1%); 25.2% versus 0.6% Fatigue (38.0% vs. 26.7%); 2.0% versus 1.2% Low rate of febrile neutropenia (0.6%, both groups) | |
Ribociclib | MONALEESA-2 | Randomized; Double-blind, Phase 3 | Postmenopausal; HR+, HER2− recurrent or metastatic BC No prior therapy for advanced disease | Primary efficacy endpoint, PFS, met at interim analysis; favors ribocilclib (Not reached vs. 14.7mo; HR 0.56; 95% CI 0.43; 0.72; P < 3.29 × 10−6) OS data immature at time of analysis ORR 40.7% versus 27.5%; P < 0.001 CBR 79.6% versus 72.8% P = 0.02 Ribociclib also favored in subgroup of patients with HR+, HER2− ABC at diagnosis (Median PFS not reached w/ribociclib vs. 16.4 mo w/placebo HR 0.45, 95% CI 0.27–0.75) | Toxicities occurring in 30% or more patients (Ribociclib vs. Placebo); Gr 3/4, Ribociclib versus Placebo Neutropenia (74.3% vs. 5.2%); 59.3% versus 0.9% Nausea (51.5% vs. 28.5%); 2.4% versus 0.6% Infections (50.3% vs. 42.4%); 4.2% versus 2.4% Fatigue (36.5% vs. 30.0%); 2.4% versus 0.9% Diarrhea (35.0% vs. 22.1%); 1.2% versus 0.9% Alopecia (33.2% vs. 15.5%); Gr 3/4 not applicable Leukopenia (32.9% vs. 3.9%); 21.0% versus 0.6% Febrile neutropenia occurred within 4 weeks in 1.5% of patients in ribociclib group vs. 0% placebo group QTc prolomgation occured in 11(3.3%) and 1 sudden death in the setting of hypokalemia and G2 QTc prolongation in the ribociclib group |
MONALEESA-7 | Double-blind, randomized, Phase III Ribociclib or placebo + tamoxifen/NSAI and goserelin | Pre- or peri-menopausal women with HR+, HER2− ABC who had received ≤ 1 line of CT and no prior ET for ABC | PFS significantly improved with ribociclib (median PFS, 23.8 vs. 13.0 months; HR 0.553; P = 9.83 × 10−8) ORR 51% versus 36% (ribociclib vs placebo) arm; P = 3.17 × 10−4) CBR 80% versus 67%; P = 3.40 × 10−4. | Most frequent all-grade AEs; ≥ 25% of patients; ribociclib vs placebo arm) Neutropenia (76% vs 8%) Hot flush (34% vs 34%) Nausea (32% vs 20%) Leukopenia (31% vs 6%) Arthralgia (30% vs 27%) Gr 3/4 Events in ≥ 5% of patients: Neutropenia (61% vs 4%) Leukopenia (14% vs 1%) Febrile neutropenia: 2% versus < 1% AEs leading to permanent discontinuation: 4% versus 3% | |
Abemaciclib | MONARCH-1 | Phase 2 single arm Abemaciclib until PD | HR+/HER2− mBC, PD after ET and CT 1–2 lines CT for metastatic disease | Confirmed ORR 19.7% CBR 42.4% Median PFS 6.0 mo Median OS 17.7 mo | Diarrhea, fatigue, and nausea most common AEs 7.6% discontinued due to AEs |
MONARCH-2 | Phase 3; randomized, double-blind placebo-controlled Abemaciclib or Placebo + Fulvestrant | HR+, HER2− ABC PD after ET No prior CT for ABC | PFS 16.4 mo versus. 9.3 mo (HR 0.553; 95% CI 0.449; 0.681; P < 0.001) Benefit consistent across subgroups ORR 35.2% versus 16.1% P < 0.001 CBR 72.2% versus 56.1% P < 0.001 | Toxicities occurring in 30% or more patients (Abemaciclib vs. Placebo); Gr 3/4, Abemaciclib vs. Placebo Diarrhea (86.4% vs. 24.7%); 13.4% versus 0.4% Neutropenia (46.0% vs. 4.0%); 26.5% versus 1.7% Nausea (45.1% vs. 22.9%); 2.7% versus 0.9% Fatigue (39.9% vs. 26.9%); 2.7% versus 0.4% Abdominal Pain (35.4% vs. 15.7%); 2.5% versus 0.9% | |
MONARCH-3 | Abemaciclib or Placebo, + NSAI | HR+, HER2− ABC No prior systemic therapy for metastatic disease | Primary efficacy endpoint, PFS, favors abemaciclib (HR 0.543; 95% CI 0.409; 0.723; P = 0.000021); benefit observed across subgroups OS data immature at time of analysis
Response Rate
All patients ORR favors abemaciclib (48.2% vs. 34.5%; P = 0.002) CBR trended better w/abemaciclib (78.0% vs. 71.5%; P = NS) Patients with measurable disease at baseline ORR favors abemaciclib (59.2% vs. 43.8%; P = 0.004) CBR favors abemaciclib (79.4% vs. 69.2%; P = 0.024) | Toxicities (30% or more patients, Abemaciclib vs. Placebo); Gr 3/4, Abemaciclib vs. Placebo Diarrhea (81.3% vs. 29.8%); 9.5% versus 1.2% Neutropenia (41.3% vs. 1.9%); 21.1% versus 1.2% Fatigue (40.1% vs. 31.7%); 1.8% versus 0% Nausea (38.5% vs. 19.9%); 0.9% versus 1.2% 1 pt with nonserious febrile neutropenia in abemaciclib arm Gr 3/4 neutropenia in 21.1%; not associated with neutropenic fever Diarrhea (Gr 3) occurred early, managed with dose reduction and antidiarrheal medications |
CDK 4/6 treatment: what are the differentiators?
What are the differentiators, current or future, that drive your decision to treat using the various endocrine options available for the treatment of metastatic breast cancer?
In terms of PFS reduction (Tables 1), it was agreed by the panel that the three CDK 4/6 inhibitors appear to be largely similar in efficacy, and, as noted above, none has as yet shown a benefit in OS. The initial discussion was focused on the differentiators, current or future, if any, which drive the decision to treat using the various endocrine options available for the treatment of mBC. The group was not entirely uniform with respect to their use of CDK 4/6 inhibitors in the first-line setting for metastatic disease. The principal drivers identified from the discussion included whether the patient was symptomatic or asymptomatic from the metastatic standpoint, whether the metastases were primarily visceral or nonvisceral, menopausal status, and the disease-free interval. Some participants reported (owing to the current lack of OS advantage) being more inclined to use endocrine therapy alone if a patient was asymptomatic with relatively indolent disease and had been off endocrine therapy for a few years, and in those with de novo, bone only metastatic disease. There was general agreement on the early use of a CDK 4/6 inhibitor in younger patients and in those with aggressive, progesterone receptor-negative (PR−) and/or symptomatic disease.
Mutation in ESR1, the gene encoding the estrogen receptor and a suspected marker of endocrine therapy resistance [16‐18], was also cited as a potentially meaningful factor to consider, and an active area of research, although among the group, it was not routinely tested for outside of a clinical study, and was not used as a determinant for CDK 4/6 inhibitor use. The group did, however, cite the potential importance of ESR1 mutation results, if available, when deciding to use the selective estrogen receptor degrader, fulvestrant or an aromatase inhibitor (AI) in combination with CDK 4/6 therapy [18]. Indeed, results from PALOMA-3 using circulating tumor DNA showed ESR1 mutation in 106 of 395 samples tested (26.8%), and all of these patients had been previously treated with an AI, whereas no ESR1 mutations were found in patients who received tamoxifen only. Also of importance from this study was that median PFS was significantly longer with the combination of palbociclib + fulvestrant as compared to placebo + fulvestrant regardless of patient’s ESR1 mutational status [19]. It was noted that new technologies for ESR1 mutational testing, such as evaluation of circulating tumor DNA, continue to be developed and, although not currently standard practice, may be routinely incorporated into testing in the near future.
Anzeige
A few participants in the group reported using CDK 4/6 inhibitors as first-line therapy in a majority of patients, citing the robust PFS improvements across all the major studies and within subgroups, in which the doublet was consistently found to be beneficial over the single-agent endocrine therapy. However, the group acknowledged that market research from the major CDK 4/6 developers showed a much lower uptake of these agents than would have been expected, based upon the clinical results; this suggests that clinicians believe they know who will benefit from the drug and who will not, or this could be a manifestation of other variables (e.g., drug cost). In reality, however, there was agreement that, based on Forest plots presented in the major clinical trials, all subgroups of patients with HR+, HER2− mBC benefit, and there is not at present a clinical feature or biomarker for use of these agents, nor is there a clinical outlier whom one could reliably predict would, or would not benefit from the use of a CDK 4/6 inhibitor with endocrine therapy.
With regard to the lack of OS benefit in the face of the robust improvements in PFS, it was suggested that none of the major trials may be sufficiently powered to detect survival benefit, and as such, pooling/meta-analysis of trial data, as well as further follow up, may be needed to adequately evaluate this endpoint. Some participants noted the results of a Southwest Oncology Group (SWOG) study showing improvement in OS with anastrozole and fulvestrant as first-line therapy [20]. Others, however, were more dismissive of the SWOG trial, citing its unplanned subgroup analyses and suggesting the OS benefit was restricted to patients naïve to adjuvant tamoxifen. Another important point raised is that OS benefit has become more difficult to attribute to the first-line therapy, since many possible treatment options are now available to the patient over time; thus determining the impact of a first-line therapy on OS will become progressively more difficult.
Barriers to use of CDK 4/6 inhibitors
What significant clinical toxicities, financial barriers, and/or common community practice misunderstandings exist regarding the use of CDK 4/6 inhibitors?
Several barriers to the widespread use of CDK 4/6 inhibitors were identified by the group. Whereas there was agreement that the addition of CDK 4/6 inhibitors to endocrine therapy resulted in overall low additional toxicity over endocrine therapy alone, there was concern over events such as fatigue and alopecia with all of the agents, and diarrhea with abemaciclib. In the case of palbociclib, the group expressed some concerns regarding alopecia; some felt incidence of events such as alopecia was similar with ribociclib, although globally the experience with ribociclib in the group was more limited.
The group discussed results presented by Finn and coworkers at 2017 ASCO showing that concerns regarding possible increased incidence or severity of future myelotoxicity upon progression on palbociclib were not substantiated, and indicating that chemotherapy delivery and efficacy post-palbociclib was not compromised [21]. The group felt this was an important point, because if patients were to develop worsened myelotoxicity later in the course of treatment, this would likely compromise the use of subsequent chemotherapies over concerns of further myelosuppression. The group also felt it important to highlight that, despite the frequent occurrence of neutropenia with these agents, the rate of febrile neutropenia was low across the trials, and the group did not report utilizing growth factor or prophylactic antibiotic support with these agents. Patient-reported outcome (PRO) and quality of life (QoL) data were also cited from ASCO 2017, which compared ribociclib and placebo (in combination with letrozole) in patients with HR+, HER2− advanced breast cancer (MONALEESA-2 trial). The results of this trial showed (at least in the case of ribociclib) that QoL was not adversely affected, and certain measures (e.g., pain reduction) trended better with the addition of the CDK 4/6 inhibitor [22].
There was discussion surrounding monitoring requirements, and how these impact the choice of CDK4/6 inhibitor. Electrocardiogram (ECG) monitoring with ribociclib, for example (Table 2), was cited as a nuisance by several members of the group. Regarding the need for complete blood cell (CBC) and other monitoring (Table 2), the panel noted the importance of keeping apprised of any prescribing information updates. Palbociclib, for example, in its most recent update, now recommends CBC to be monitored prior to the start of therapy and at the beginning of each cycle, as well as on day 15 of the first 2 cycles, and then less frequently (every 3 months) [23]. The update may be beneficial for patients who are not inclined to return monthly for CBC monitoring and for physicians who prefer to follow patients at longer intervals.
Agent (trade name) | Year approved | Indication | Most common adverse events and required monitoring |
|---|---|---|---|
Palbociclib (Ibrance®) | 2015 | HR+, HER2− Advanced or metastatic breast cancer, in combination with: A. An AI as initial endocrine based therapy in postmenopausal women; or B. Fulvestrant, in women with disease progression following endocrine therapy. | (Incidence ≥ 10%) Neutropenia, infections, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, asthenia, pyrexia Required Monitoring: CBC |
Ribociclib (Kisqali®) | 2017 | Postmenopausal women with HR+, HER2− Advanced or metastatic breast cancer in combination with an AI as initial endocrine-based therapy. | (Incidence > 20%) Neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, back pain Required Monitoring: QT interval prolongation, Electrocardiograms (ECGs), Electrolytes, Liver Function Tests (LFTs), CBC |
Abemaciclib (Verzenio™) | 2017 | In combination with fulvestrant for HR+, HER2−, Advanced or metastatic breast cancer with disease progression following endocrine therapy; or As monotherapy for HR+, HER2−, Advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting | (Incidence ≥ 20%) Diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, thrombocytopenia Required Monitoring: Liver Function Tests (LFTs), CBC, Monitor for venous thrombosis and pulmonary embolism |
Delays in institution of therapy due to the need for dose reductions were also cited as a significant and costly problem. Drug wastage was raised as an important issue in light of rising healthcare costs. Some participants noted that ribociclib dose reduction was easier, owing to its blister packaging. Frequent and appropriate dose reductions were reported as necessary for both hematologic (e.g., neutropenia) and nonhematologic toxicities (e.g., fatigue). Lastly, despite the importance of “having the conversation with the patient” and offering CDK 4/6 inhibitors upfront (in absence of any contraindications), some in the group noted that patients may be inclined to refuse the treatment if the drug costs are prohibitive. Indeed, it was agreed that co-pays of up to 20% could present a significant financial hardship for many patients, and, given the lack of survival benefit, there was some discussion that PFS benefit alone might not justify the cost. It was also noted by the group that the use of CDK 4/6 inhibitors may not ultimately be found to be a cost-effective intervention; despite this, however, it was felt that cost alone should not be a deciding factor on whether to use these agents [24‐26].
Sequencing Therapies for ER+/HER2– MBC
How would you approach patients that have progressed on a CDK 4/6 inhibitor?
With respect to the current status of CDK 4/6 inhibitors in the sequence of treatment, the question was raised about “saving” CDK 4/6 inhibitor use for a later line of therapy. The group cited the higher magnitude of PFS benefit associated with combination therapy upfront, as opposed to using CDK 4/6 inhibitor in combination with fulvestrant at a later time. There was agreement that the first-line therapy a patient receives is generally the one they will continue for the longest period of time, and that, in accordance with the general principles of oncology, the most effective, and the least toxic therapies should be used first. The group then discussed the management of patients who progress on AI monotherapy after more than 1 year of disease control. Possible considerations included considering ESR1 mutational status to determine if a switch to fulvestrant would be appropriate. Fulvestrant therapy was also thought to be beneficial in this scenario as it assures compliance due to its mode of administration. They acknowledged results from the To Reverse ENDocrine resistance (TREND) trial, which demonstrated that highly selected patients may benefit from adding palbociclib to long-term AI therapy after progression (with no change in endocrine therapy), with the caveat that this was a small study (N = 115) and the approach should not be used routinely in the absence of larger confirmatory data [27]. This trial also showed activity of single-agent palbociclib in this setting (CBR, 60%), and in this regard, it should also be noted that all three agents have been shown to have at least some activity as a monotherapy, although at present, only abemaciclib is approved as a single-agent treatment (Table 2) [2‐4, 10, 27‐29]
The group was generally in agreement on the upfront use of an AI with a CDK 4/6 inhibitor, followed by (upon progression) fulvestrant or exemestane with a mammalian target-of-rapamycin (mTOR) inhibitor (e.g. everolimus). The incorporation of everolimus was felt to be associated with additional toxicity, albeit manageable toxicity with the incorporation of additional measures (e.g., steroid-based mouthwash). The data supporting the combination of fulvestrant and everolimus were cited as the PrECOG 0102 data presented at San Antonio Breast Cancer Symposium (SABCS) 2016 [30]. Notably, patients in this study had not been treated with prior CDK 4/6 inhibitors, and another important unresolved issue noted by the group (and not addressed in PrECOG 0102) was whether CDK 4/6 inhibitor therapy should be continued upon progression.
Anzeige
There was agreement that data on switching between CDK 4/6 inhibitors are not yet available, and while the label for abemaciclib does not exclude patients who previously received a CDK4/6 inhibitor, the Monarch-1 study did not allow prior CDK4/6 inhibitors. Efficacy data for abemaciclib monotherapy following progression on a CDK 4/6 inhibitor are therefore not yet available. The potential use of CDK 4/6 inhibitors in combination with tamoxifen in pre- and perimenopausal women was also discussed, and in this regard, the panel now recognizes recently reported results from MONALEESA-7 (SABCS 2017) which confirm a benefit of using ribociclib in combination with tamoxifen (and goserelin) in this patient population (Table 1) [14]. At present, there are no data on using tamoxifen (without ovarian suppression) and a CDK 4/6 inhibitor.
Biomarkers for CDK 4/6 inhibitors
What biomarkers, if any, have been shown to predict benefit, or lack thereof, when using CDK4/6 inhibitors (e.g., ESR1, CND1 amplification, p16 loss, or RB1 expression)?
Regarding the use of biomarkers to predict responses in patients treated with CDK 4/6 inhibitors, the panel noted the results from PALOMA-1, in which markers such as cyclin D1 amplification and p16 loss did not reliably predict response to palbociclib [5, 31]. They agreed clinicians should not use biomarkers to make treatment decisions, and the only proven biomarker of response per se is the estrogen receptor itself. The group also recognized the need for phosphorylated pRb in order for the CDK 4/6 inhibitors to work, and some of the group said they would be reluctant to start on a CDK 4/6 inhibitor, if it was known the tumor had loss of pRb. This is perhaps most relevant for a patient that had progressed on single-agent AI and for whom such information could be potentially available, whereas for most patients this would not be known in the up front setting. The group thought that markers of response early in the course of single-agent therapy are urgently needed, and cited efforts underway to find markers such as mutational load in serum during therapy. At present, however, it was agreed that such markers are not available.
Summary and key points
Overall, the group viewed the addition of CDK 4/6 inhibitors as a valuable therapeutic option available to women with HR+, HER2−, mBC, with the caveat that additional research is needed to gain clarification on several important issues such as treatment biomarkers, optimal duration of therapy, continuation of CDK4/6 inhibitors, and/or a switch to a different drug in the same class following disease progression. In light of this BCTEG roundtable discussion, the following expert opinion statements can be made:
-
Level 1 evidence now supports use of a CDK 4/6 inhibitor in combination with endocrine therapy for patients with HR+, HER2−, mBC as first-line treatment.
-
Currently, there are no biomarkers that reliably define patients who will or will not benefit from the addition of a CDK 4/6 inhibitor to endocrine therapy; ESR1 mutational status should not restrict use of a CDK 4/6 inhibitor.
-
Financial considerations may limit the use of these agents, and treatment-related toxicities such as diarrhea and fatigue may be dose limiting; although neutropenia is a frequent occurrence with these agents, the rate of febrile neutropenia is low.
-
Additional research is needed to identify the optimal sequencing of CDK 4/6 inhibitors in relation to other therapies as well as optimal duration of therapy; at present, use in the upfront setting is better than waiting for a later line of therapy or adding after endocrine therapy has started.
Finally, the group agreed that CDK 4/6 inhibitors are an important new class of drugs in the management of patients with inoperable breast cancer. In addition, it was recognized that at present, breast cancer is leading the field in clinical experience with CDK 4/6 inhibitors, and research currently underway in breast cancer (e.g., optimal duration of therapy, use in combination with other treatments) will be of value to many other cancer types such as lung cancer, glioblastoma, and melanoma. It was noted, for example, that, although their use in combination with endocrine therapy is now well established, due to their antiproliferative activity, CDK 4/6 inhibitors might not be optimally combined with other emergent therapies, such as immunotherapy (which requires T cell proliferation), and might in fact act antagonistically with some types of chemotherapy. These and other combinations await further evaluation in clinical trials.
Anzeige
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.